Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 61.12

-2.3%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: atticus4paws	1/31/2019 10:18:32 AM
	Read Replies (1) of 52153

In the interest filling the void that's developed at SI over the last few days (except for Miljenko), maybe someone can chime in on a question I have from a Twitter instigated tangent. I'll try to make it short. :) What's what vis-a-vis THRB agonists (MDGL,VKTX) versus FGF21 as pathways for NAFLD/NASH treatment? BMY still has a PEG FGF21 drug in it's pipeline chart when Ph2 results were clearly inferior to MDGL & VKTX results (this doesn't sway me one way or the other, could just be BMY's suboptimal drug). David Grainger tweeted about a study showing BMP-9 administration in mice upregulated FGF21 expression in a study of high-fat chow induced obesity. I think Roche or someone might be exploring FGF21 in trials as well. So, any opinions on FGF21 vs THRB (I realize that something else entirely or many may win)?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next